| Nov 14 |
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
|
| Nov 14 |
ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027
|
| Nov 14 |
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...
|
| Nov 14 |
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
Adaptimmune GAAP EPS of -$0.01 beats by $0.07, revenue of $40.9M beats by $20.41M
|
| Nov 13 |
Adaptimmune to engage in restructuring; 33% headcount reduction
|
| Nov 13 |
Adaptimmune Reports Q3 2024 Financial and Business Updates
|
| Nov 13 |
Adaptimmune reports positive data in mid-stage trial of its sarcoma treatment
|
| Nov 13 |
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
